深交所向广东嘉应制药股份有限公司、李能、游永平、肖巧霞发出监管函

Group 1 - The core issue involves regulatory actions taken against Jiaying Pharmaceutical for failing to disclose related party transactions properly, which amounted to approximately 8.7558 million yuan, representing 1.15% of the company's latest audited net assets [1] - The company and its executives, including the chairman and general manager, were found to have violated multiple provisions of the stock listing rules, indicating a lack of diligence and responsibility in their roles [1] - The company is urged to learn from this incident and ensure compliance with relevant laws and regulations, including the Securities Law and Company Law, to prevent future occurrences [1] Group 2 - For the first half of 2025, Jiaying Pharmaceutical's revenue composition was heavily weighted towards the pharmaceutical industry, accounting for 99.96%, with other businesses making up only 0.04% [2] - As of the report date, Jiaying Pharmaceutical's market capitalization was 3.4 billion yuan [2]